An Isomünchnone-Based Method for the Synthesis of Highly Substituted 2(1H)-Pyridones
摘要:
1-(Benzenesulfonyl-diazoacetyl)-pyrrolidin-2-one was prepared by a diazo transfer of 1-(benzenesulfonylacetyl)-pyrrolidin-2-one with p-acetamidobenzenesulfonyl azide and triethylamine. Treatment; of the diazoimide with a catalytic quantity of rhodium(II) acetate resulted in the formation of an isomunchnone dipole, which underwent bimolecular trapping with various dipolarophiles in high yield. The initially formed cycloadducts were not isolable or observed, as they all readily underwent ring opening to give the 3-hydroxy-2(1H)-pyridone ring system. The 3-hydroxy-2(1H)-pyridones were readily converted to the corresponding triflates, which function as suitable substrates in various types of palladium-catalyzed cross-coupling reactions. Commercial tetrakis(triphenylphoshine)palladium was found to be a particularly effective catalyst for the cross-coupling with aryl, vinyl, and acetylenic partners. An application of the method to the synthesis of the indolizidine alkaloid (+/-)-ipalbidine was carried out in eight steps in 17% overall yield. The angiotensin-converting enzyme inhibitor (-)-A58365A was also synthesized by a process based on the [3 + 2]-cycloaddition reaction of a phenylsulfonyl substituted isomunchnone intermediate. The starting material for this process was prepared from L-pyroglutamic acid and involved using a diazo phenylsulfonyl substituted pyrrolidine imide. Treatment of the diazoimide with Rh-2(OAc)(4) in the presence of methyl vinyl ketone afforded a 3-hydroxy-2-pyridone derivative, which was subsequently converted to the ACE inhibitor in six additional steps.
[EN] ARYL HETEROBICYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ARYLÉS EN TANT QUE BLOQUEURS DU CANAL POTASSIQUE SHAKER KV1.3
申请人:DE SHAW RES LLC
公开号:WO2021071832A1
公开(公告)日:2021-04-15
A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is described, where the substituents are as defined herein. Pharmaceutical compositions including the same and method of using the same are also described.
In Situ Generation and Intramolecular Schmidt Reaction of Keto Azides in a Microwave-Assisted Flow Format
作者:Thomas O. Painter、Paul D. Thornton、Mario Orestano、Conrad Santini、Michael G. Organ、Jeffrey Aubé
DOI:10.1002/chem.201100768
日期:2011.8.22
Go with the flow! A method for conversion of keto halides to lactams by means of sequential azidation and intramolecularSchmidtreaction in a combined flowformat is described (see scheme; MWI=microwave irradiation, TFA=trifluoroacetic acid).
Hypervalent organoiodine reagents in the transannular functionalisation of medium-sized lactams: synthesis of 1-azabicyclo compounds
作者:R. L. Dorta、C. G. Francisco、E. Suárez
DOI:10.1039/c39890001168
日期:——
produced by photolysis of medium-sizedlactams 7-heptanelactam (1), 8-octanelactam (3), and 9-nonanelactam (6) in the presence of (diacetoxyiodo)benzene (DIB) and iodine, undergo transannular hydrogen abstraction to afford intermolecularly functionalised compounds such as oxoindolizidines (4) and (5) and the 1-azabicyclo[5.3.0]decan-2-one (7) that are obtained in high yield from lactams (3) and (6), respectively
Intramolecular Schmidt reactions of alkyl azides with ketals and enol ethers
作者:Craig J. Mossman、Jeffrey Aubé
DOI:10.1016/0040-4020(96)00037-3
日期:1996.3
The ketals or enol ethers of 1,5-azidoketones were converted into lactams using a two-stage process. Treatment of the ketals and enol ethers with acid (trifluoroacetic acid, triflic acid, or trimethylsilyl triflate) afforded an oxonium ion which reacted with the tethered azide to give a 1,1-azido-alkoxy intermediate. Bond reorganization led to an iminium ether that was reacted with sodium iodide in
HETEROCYCLIC COMIPOUND AS CDK-HDAC DUAL PATHWAY INHIBITOR
申请人:Hangzhou Innogate Pharma Co., Ltd.
公开号:US20220024916A1
公开(公告)日:2022-01-27
The invention provides compounds of formula (I) as shown below, as well as pharmaceutically acceptable salts, hydrates or solvates thereof. The invention also provides pharmaceutical compositions of these compounds, methods for their preparation, and their use in the treatment of diseases and disorders (including cancers).